tiprankstipranks
DENTSPLY SIRONA Inc (IT:1XRAY)
:1XRAY
Italy Market
1XRAY
DENTSPLY SIRONA
RESEARCH TOOLSreports

DENTSPLY SIRONA (1XRAY) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

1XRAY Analyst Ratings

Hold
12Ratings
Hold
2 Buy
9 Hold
1 Sell
Based on 12 analysts giving stock ratings to
DENTSPLY
SIRONA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1XRAY Stock 12 Month Forecast

Average Price Target

€12.01
▲(3.16% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is €12.01 with a high forecast of €14.71 and a low forecast of €7.79. The average price target represents a 3.16% change from the last price of €11.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","15":"€15","8.25":"€8.25","10.5":"€10.5","12.75":"€12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.71281881,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€14.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.00825652875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.78913937,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,8.25,10.5,12.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.505,11.751755293076924,11.998510586153847,12.24526587923077,12.492021172307693,12.738776465384616,12.985531758461539,13.232287051538462,13.479042344615385,13.725797637692308,13.97255293076923,14.219308223846154,14.466063516923077,{"y":14.71281881,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.505,11.543712040673078,11.582424081346154,11.621136122019232,11.659848162692308,11.698560203365385,11.737272244038461,11.775984284711539,11.814696325384615,11.853408366057693,11.892120406730768,11.930832447403846,11.969544488076922,{"y":12.00825652875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.505,11.219164566923078,10.933329133846154,10.647493700769232,10.361658267692308,10.075822834615385,9.789987401538461,9.504151968461539,9.218316535384616,8.932481102307692,8.646645669230768,8.360810236153846,8.074974803076923,{"y":7.78913937,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.231,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.999,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.905,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.835,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.676,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.648,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.855,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.255,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.634,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.718,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.505,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€14.71Average Price Target€12.01Lowest Price Target€7.79
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on IT:1XRAY
Michael Petusky
Barrington
Barrington
€14.71→€12.98
Buy
11.53%
Upside
Reiterated
08/10/26
Dentsply Sirona price target lowered to $15 from $17 at BarringtonDentsply Sirona price target lowered to $15 from $17 at Barrington
Robert W. Baird Analyst forecast on IT:1XRAY
Jeff Johnson
Robert W. Baird
Robert W. Baird
€12.12→€12.98
Hold
11.53%
Upside
Reiterated
08/07/26
Dentsply Sirona price target raised to $15 from $14 at BairdDentsply Sirona price target raised to $15 from $14 at Baird
Stifel Nicolaus Analyst forecast on IT:1XRAY
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
€12.12
Hold
4.09%
Upside
Reiterated
08/07/26
Stifel Nicolaus Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)
Evercore ISI Analyst forecast on IT:1XRAY
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
€12.12
Hold
4.09%
Upside
Reiterated
08/07/26
Evercore ISI Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Barclays Analyst forecast on IT:1XRAY
Glen Santangelo
Barclays
Barclays
€7.79
Sell
-33.08%
Downside
Reiterated
08/07/26
Barclays Sticks to Their Sell Rating for DENTSPLY SIRONA (XRAY)
Needham Analyst forecast on IT:1XRAY
David Saxon
Needham
Needham
―
Hold
―
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)
Piper Sandler Analyst forecast on IT:1XRAY
Jason Bednar
Piper Sandler
Piper Sandler
€12.12
Hold
4.09%
Upside
Reiterated
08/07/26
Piper Sandler Reaffirms Their Hold Rating on DENTSPLY SIRONA (XRAY)
William Blair Analyst forecast on IT:1XRAY
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: Astellas Pharma (Other OTC: ALPMF), DENTSPLY SIRONA (NASDAQ: XRAY) and IDEAYA Biosciences (NASDAQ: IDYA)
BMO Capital Analyst forecast on IT:1XRAY
Vik Chopra
BMO Capital
BMO Capital
€10.39→€11.25
Hold
-3.34%
Downside
Reiterated
08/06/26
BMO Capital Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Morgan Stanley Analyst forecast on IT:1XRAY
Erin Wright
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Leerink Partners Analyst forecast on IT:1XRAY
Michael Cherny
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
06/12/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), DENTSPLY SIRONA (NASDAQ: XRAY) and Climb Bio (NASDAQ: CLYM)
Bank of America Securities Analyst forecast on IT:1XRAY
Allen Lutz
Bank of America Securities
Bank of America Securities
€14.71
Buy
26.40%
Upside
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on IT:1XRAY
Kevin Caliendo
UBS
UBS
€15.58→€14.71
Buy
26.40%
Upside
Reiterated
05/07/26
Dentsply Sirona price target lowered to $17 from $18 at UBSDentsply Sirona price target lowered to $17 from $18 at UBS
Citi Analyst forecast on IT:1XRAY
Daniel Grosslight
Citi
Citi
€8.65→€9.09
Sell
-21.93%
Downside
Reiterated
05/06/26
DENTSPLY SIRONA (XRAY) Receives a Sell from Citi
Mizuho Securities Analyst forecast on IT:1XRAY
Steven Valiquette
Mizuho Securities
Mizuho Securities
€13.85→€12.12
Hold
4.09%
Upside
Reiterated
05/06/26
Dentsply Sirona price target lowered to $14 from $16 at MizuhoDentsply Sirona price target lowered to $14 from $16 at Mizuho
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on IT:1XRAY
Michael Petusky
Barrington
Barrington
€14.71→€12.98
Buy
11.53%
Upside
Reiterated
08/10/26
Dentsply Sirona price target lowered to $15 from $17 at BarringtonDentsply Sirona price target lowered to $15 from $17 at Barrington
Robert W. Baird Analyst forecast on IT:1XRAY
Jeff Johnson
Robert W. Baird
Robert W. Baird
€12.12→€12.98
Hold
11.53%
Upside
Reiterated
08/07/26
Dentsply Sirona price target raised to $15 from $14 at BairdDentsply Sirona price target raised to $15 from $14 at Baird
Stifel Nicolaus Analyst forecast on IT:1XRAY
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
€12.12
Hold
4.09%
Upside
Reiterated
08/07/26
Stifel Nicolaus Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)
Evercore ISI Analyst forecast on IT:1XRAY
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
€12.12
Hold
4.09%
Upside
Reiterated
08/07/26
Evercore ISI Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Barclays Analyst forecast on IT:1XRAY
Glen Santangelo
Barclays
Barclays
€7.79
Sell
-33.08%
Downside
Reiterated
08/07/26
Barclays Sticks to Their Sell Rating for DENTSPLY SIRONA (XRAY)
Needham Analyst forecast on IT:1XRAY
David Saxon
Needham
Needham
―
Hold
―
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)
Piper Sandler Analyst forecast on IT:1XRAY
Jason Bednar
Piper Sandler
Piper Sandler
€12.12
Hold
4.09%
Upside
Reiterated
08/07/26
Piper Sandler Reaffirms Their Hold Rating on DENTSPLY SIRONA (XRAY)
William Blair Analyst forecast on IT:1XRAY
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: Astellas Pharma (Other OTC: ALPMF), DENTSPLY SIRONA (NASDAQ: XRAY) and IDEAYA Biosciences (NASDAQ: IDYA)
BMO Capital Analyst forecast on IT:1XRAY
Vik Chopra
BMO Capital
BMO Capital
€10.39→€11.25
Hold
-3.34%
Downside
Reiterated
08/06/26
BMO Capital Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Morgan Stanley Analyst forecast on IT:1XRAY
Erin Wright
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Leerink Partners Analyst forecast on IT:1XRAY
Michael Cherny
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
06/12/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), DENTSPLY SIRONA (NASDAQ: XRAY) and Climb Bio (NASDAQ: CLYM)
Bank of America Securities Analyst forecast on IT:1XRAY
Allen Lutz
Bank of America Securities
Bank of America Securities
€14.71
Buy
26.40%
Upside
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on IT:1XRAY
Kevin Caliendo
UBS
UBS
€15.58→€14.71
Buy
26.40%
Upside
Reiterated
05/07/26
Dentsply Sirona price target lowered to $17 from $18 at UBSDentsply Sirona price target lowered to $17 from $18 at UBS
Citi Analyst forecast on IT:1XRAY
Daniel Grosslight
Citi
Citi
€8.65→€9.09
Sell
-21.93%
Downside
Reiterated
05/06/26
DENTSPLY SIRONA (XRAY) Receives a Sell from Citi
Mizuho Securities Analyst forecast on IT:1XRAY
Steven Valiquette
Mizuho Securities
Mizuho Securities
€13.85→€12.12
Hold
4.09%
Upside
Reiterated
05/06/26
Dentsply Sirona price target lowered to $14 from $16 at MizuhoDentsply Sirona price target lowered to $14 from $16 at Mizuho
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering DENTSPLY SIRONA

3 Months
Kevin CaliendoUBS
Success Rate
5/14 ratings generated profit
36%
Average Return
-3.79%
Copying Kevin Caliendo's trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -3.79% per trade.
1 Year
Kevin CaliendoUBS
Success Rate
3/14 ratings generated profit
21%
Average Return
-12.23%
Copying Kevin Caliendo's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -12.23% per trade.
2 Years
Kevin CaliendoUBS
Success Rate
3/14 ratings generated profit
21%
Average Return
-23.71%
Copying Kevin Caliendo's trades and holding each position for 2 Years would result in 21.43% of your transactions generating a profit, with an average return of -23.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1XRAY Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
3
4
4
1
Buy
4
2
0
0
1
Hold
10
9
8
10
11
Sell
3
4
4
3
2
Strong Sell
0
0
0
0
0
total
17
18
16
17
15
In the current month, 1XRAY has received 2 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. 1XRAY average Analyst price target in the past 3 months is 12.01.
Each month's total comprises the sum of three months' worth of ratings.

1XRAY Financial Forecast

1XRAY Earnings Forecast

Next quarter’s earnings estimate for 1XRAY is €0.29 with a range of €0.23 to €0.36. The previous quarter’s EPS was €0.45. 1XRAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.49% of the time in the same period. In the last calendar year 1XRAY has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1XRAY is €0.29 with a range of €0.23 to €0.36. The previous quarter’s EPS was €0.45. 1XRAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.49% of the time in the same period. In the last calendar year 1XRAY has Performed in-line its overall industry.

1XRAY Sales Forecast

Next quarter’s sales forecast for 1XRAY is €752.67M with a range of €737.69M to €776.75M. The previous quarter’s sales results were €779.36M. 1XRAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.36% of the time in the same period. In the last calendar year 1XRAY has Performed in-line its overall industry.
Next quarter’s sales forecast for 1XRAY is €752.67M with a range of €737.69M to €776.75M. The previous quarter’s sales results were €779.36M. 1XRAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.36% of the time in the same period. In the last calendar year 1XRAY has Performed in-line its overall industry.

1XRAY Stock Forecast FAQ

What is IT:1XRAY’s average 12-month price target, according to analysts?
Based on analyst ratings, DENTSPLY SIRONA Inc’s 12-month average price target is 12.01.
    What is IT:1XRAY’s upside potential, based on the analysts’ average price target?
    DENTSPLY SIRONA Inc has 3.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DENTSPLY SIRONA Inc a Buy, Sell or Hold?
          DENTSPLY SIRONA Inc has a consensus rating of Hold, which is based on 2 buy ratings, 9 hold ratings and 1 sell ratings.
            What is DENTSPLY SIRONA Inc’s share price target?
            The average share price target for DENTSPLY SIRONA Inc is 12.01. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €14.71 ,and the lowest forecast is €7.79. The average share price target represents 3.16% Increase from the current price of €11.64.
              What do analysts say about DENTSPLY SIRONA Inc?
              DENTSPLY SIRONA Inc’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of DENTSPLY SIRONA Inc?
                To buy shares of IT:1XRAY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.